ABAlba López Bravo

Alba López Bravo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alba López Bravo has a total of 218 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Migraña en hombres

    by Alba López-Bravo

    El contenido completo estará disponible en breve. ¡Gracias por tu paciencia!

  • Open Access

    Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort

    by Edoardo Caronna, Rut Mas-De-Les-Valls, Gabriella Egeo, Manuel Millán Vázquez, Candela Nieves Castellanos, Javier A Membrilla, Gloria Vaghi, Joana Rodríguez-Montolio, Neus Fabregat Fabra, Francisco Sánchez Caballero, et al.

    Background: The International Headache Society has proposed new treatment goals for migraine prevention in real world, as a way to set higher standards of care. This study provides the first assessment of the proportion of individuals achieving them after 6 months of migraine-specific treatment with anti-CGRP monoclonal antibodies (MAbs). Methods: This was a prospective, real-world, European multicenter study, including adults with migraine treated with anti-CGRP MAbs (EUREkA cohort). We assessed the proportions of individuals in each treatment goal category–migraine freedom (no monthly migraine days [MMD]); optimal control (< 4 MMD), modest control (4–6 MMD); insufficient control (>6 MMD)–after 6 months of treatment. We also assessed the proportion of individuals with ≥50% reduction in MMD in the insufficient control group. Results: Of the 5818 individuals in the EUREkA cohort, 4963 had 6 months data. Of these, 82.3% (4086/4963) were females and the median age was 48.0 [40.0–55.0] years. At baseline, the median monthly headache days [MHD] and MMD were 20.0 [13.3–28.0] and 15.0 [10.0–20.0], respectively. All participants were classified as having insufficient headache control (>6 MMD) at baseline. At month 6, 6.9% (342/4963) had migraine freedom, 22.9% (1137/4963) optimal control, 24.6% (1223/4963) modest control and 45.6% (2261/4963) insufficient control. In the insufficient control group, 27.1% (613/2261) had ≥50% reduction in MMD. Conclusions: High standards of care, defined as optimal disease control or even migraine freedom, are achieved in real-world settings with anti-CGRP MAbs in approximately 30% of individuals with a high migraine burden. These findings highlight the need to expand global access to these treatments. Future studies should explore whether initiating migraine-specific preventive treatments earlier could further reduce residual migraine days in responders, enabling a larger proportion of patients to achieve optimal disease control.


  • Open Access

    ¿Está mejorando la formación en cefaleas durante la residencia en España? Estudio comparativo a 10 años desde la doble perspectiva de residentes y tutores

    by A.B. Gago-Veiga, V. González-Quintanilla, J. Camiña, J. Díaz-De-Terán, N. González-García, M. Torres-Ferrus, A. López-Bravo, Á.L. Guerrero-Peral, R. Belvís, P. Pozo-Rosich

  • Open Access

    Diagnóstico y tratamiento de la hipotensión ortostática neurogénica

    by Alba López-Bravo

    La hipotensión ortostática (HO) se define por la caída sostenida de la presión arterial sistólica en al menos 20 o 10 mmHg...

  • Open Access

    Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real‐life multicenter study

    by Julia Peris-Subiza, Víctor Obach, Daniel Guisado-Alonso, Fernando Velasco Juanes, Rocío Álvarez Escudero, María Martín Bujanda, Sonsoles Aranceta, Aintzine Ruisánchez, Natalia Roncero, Ane Mínguez-Olaondo, et al.

    Background: Patients with migraine aged ≥65 years old are underrepresented in clinical trials. This study compares effectiveness, excellent response, and tolerability of galcanezumab in patients ≥65 years and those younger than 65 years, specifically assessing age as a predictor of response. Methods: This real‐life, multicenter cohort study included patients with chronic or high‐frequency episodic migraine who did not respond to more than or equal to three preventive drugs, treated with galcanezumab, and followed for 12 months from 12 Spanish hospitals, between November 2019 and January 2022. Effectiveness was defined as ≥50% reduction in monthly headache days (MHD), and excellent response as ≥75% reduction at 6 months. Tolerability was based on the percentage of patients discontinuing due to adverse events. Results: We included 1055 patients (934 patients p = 0.045], but lower HIT‐6 scores [67 (IQR 63–72) vs. 69 (66–73), p < 0.001]. Effectiveness was similar across age groups at 3 (57.0% vs. 48.8%, p = 0.090), 6 (57.0% vs. 51.8%, p = 0.281), and 12 months (52.1% vs. 51.4%, p = 0.889). However, excellent response was more frequent in the ≥65 years group at 3 months (32.2% vs. 23.1%, p = 0.028) and 6 months (33.9% vs. 23.5%, p = 0.012), with a non‐significant difference at 12 months (33.1% vs. 25.4%, p = 0.071). Tolerability was comparable within age groups (5.8% discontinuation due to adverse effects in patients ≥65 years vs. 6.7% in patients p = 0.837). Age was independently associated with effectiveness (adjusted odds ratio [aOR]: 1.02; 95% confidence interval [CI]: 1.004–1.03) and excellent response (aOR: 1.02; 95% CI: 1.01–1.04). A statistically significant association was found in the logistic regression model for excellent response when age was dichotomized at 65 years, with increasing age linked to a higher likelihood of an excellent treatment response (aOR: 1.79; 95% CI: 1.13–2.82, p = 0.012). Conclusions: Galcanezumab is as effective and well‐tolerated in patients aged ≥65 years as in younger patients but older patients showed a higher rate of excellent response. Age is associated with a better response to galcanezumab. image


  • Open Access

    Autonomic dysfunction in patients with episodic cluster headache during remission period

    by Alba López-Bravo, Elena Bellosta Diago, Marisa de la Rica Escuín, Laura Díez Galán, Sonia Santos Lasaosa

    Background: The hypothalamus is involved in cluster headache (CH) pathophysiology and is a hub for autonomic control. While cranial autonomic symptoms are prominent during attacks, other autonomic manifestations may be present in CH. This study aims to explore the autonomic nervous system (ANS) in patients with CH during remission period. Methods: Cross-sectional study including 30 CH and 30 age- and sex-matched controls. We analysed time- and frequency-domain parameters of heart rate variability (HRV) and active orthostatic tests. To investigate the sympathetic nervous system, plasma norepinephrine (NE) levels were determined. All assessments were performed during remission period. Results: All HRV parameters were lower in CH; the percentage of adjacent R-R intervals that differ by more than 50 milliseconds (pNN50) and standard deviation of normal-to-normal R-R intervals in 24 h (SDNN) were significantly lower in CH (pNN50, 31.0 [5.3–44.3] vs. 44.5 [25.8–58.5], p = 0.043; SDNN, 79.6 ± 42.6 vs. 99.6 ± 42.6, p = 0.004). All other time-domain parameters, including the root mean square of successive R-R differences (RMSSD) were lower in CH than in controls (RMSSD 59.5 ± 36.9 vs. 77.3 ± 39.4, p = 0.077). Compared to controls, mean HR was significantly higher in CH (64.2 [59.6–75.8] vs. 60.4 [57.3–62.7], p = 0.038). Supine and upright NE levels were significantly higher in CH, (supine 228.9 [161.6-324.1] vs. 209.9 [151.2-314.1], p = 0.015; standing 376.1 [264.6-527.8 vs. 327.4 [256.4-400.9], p = 0.019). Conclusions: The present study indicates a significant decrease in HRV and an upward trend of plasmatic NE levels in CH during remission periods, suggesting an imbalance of the ANS in this state. Graphical


  • Patient satisfaction with calcitonin gene‐related peptide monoclonal antibodies in migraine: A multicenter prospective cohort study

    by Alba López‐Bravo, Ane Mínguez‐Olaondo, Candela Nieves‐Castellanos, Marta Ruibal‐Salgado, Noemí Morollón Sánchez‐Mateos, María Pilar Navarro‐Pérez, Alicia Alpuente, Marta Torres‐Ferrús, Jésica García‐Ull, Ana Gago‐Veiga, et al.

    Background: Calcitonin gene‐related peptide monoclonal antibodies (CGRP mAbs) are the first migraine‐specific prophylactic medication. Clinical data regarding patient treatment satisfaction (TS) with CGRP mAbs are limited. Methods: A multicenter prospective cohort study was conducted in patients with ≥8 headache days/month who started treatment with erenumab, galcanezumab, or fremanezumab. Monthly migraine days (MMD), monthly headache days (MHD), Migraine Disability Assessment (MIDAS), and the six‐item Headache Impact Test (HIT‐6) scores were collected. Patients’ satisfaction with treatment (effectiveness, convenience, side effects, and global satisfaction) was assessed by the Treatment Satisfaction Questionnaire for Medication, version 1.4 (TSQM‐1.4©). Results: A total of 400 patients were included. The median (interquartile range [IQR]) TS scores were high (≥70%) across all domains of the TSQM‐1.4 after 3 and 6 months of CGRP mAb therapy: 72.2 (50.0–83.3) and 83.3 (61.1–88.9) for effectiveness, 83.3 (72.2–100) and 83.3 (77.8–100) for convenience, and finally, a score of 78.6 (50.0–92.9) and 85.7 (71.4–92.9) for global satisfaction. The median (IQR) reduction in MHD and MMD was 10.0 (3.0–17.0; p < 0.001) and 8.0 (4.0–12.0; p < 0.001) days after 3 months of treatment, and 10.0 (3.0–17.0; p < 0.001) and 9.0 (5.0–17.0; p < 0.001) days after 6 months. The median (IQR) HIT‐6 score decreased from 68.0 (65.0–72.0) to 60.0 (51.0–66.0; p < 0.001) at Month 3 and to 56.0 (48.0–64.0; p < 0.001) at Month 6. Finally, the median (IQR) MIDAS score decreased from 70 (40.0–120.0) to 24 (7.8–60.0; p < 0.001) and 17 (5.0–45.0; p < 0.001) at Months 3 and 6, respectively. The median change from baseline in MMD was significantly associated with effectiveness at 3 ( β = −0.93, 95% CI −1.34 to −0.53; p < 0.001) and 6 months ( β = −1.56, 95% CI −2.15 to −0.97; p < 0.001). Similarly, reductions in MMD were significantly associated with the global satisfaction dimension of the questionnaire ( β = −0.82, 95% CI −1.27 to −0.37; p < 0.001) and ( β = −1.80, 95% CI −2.42 to −1.18; p < 0.001). Conclusions: Most patients were satisfied with CGRP mAbs’ effectiveness, tolerability, and convenience in a real‐world setting. Interestingly, increasing TS was associated with meaningful reductions in frequency, impact, and disability caused by migraine.


  • Open Access

    Knowledge about oral preventive treatments in patients with migraine: A nationwide study

    by A. López-Bravo, S. Quintas, A. Mínguez-Olaondo, A. Alpuente, C. Nieves-Castellanos, M. Pilar Navarro-Pérez, S. Pérez-Pereda, A. Layos Romero, C. Calle de Miguel, D. García-Azorín, et al.

  • Effectiveness and safety of anti-CGRP monoclonal antibodies for migraine in patients over 65 years: a systematic review

    by Albert Muñoz-Vendrell, Alba López-Bravo, Almudena Layos-Romero, Francisco J. Alberola-Amores, María Obdulia Lozano Caballero, Antonio Sánchez-Soblechero, Cristian Morales-Hernández, María Victoria Castro-Sánchez, María Pilar Navarro-Pérez, María Rocío Córdova-Infantes, et al.

    Migraine patients over 65 years have been excluded from pivotal anti-CGRP monoclonal antibody trials leaving limited real-life data on effectiveness and safety in this population. This review aims to summarize available evidence on treatment response and safety for older patients. A PubMed and Cochrane Controlled Register of Trials (CENTRAL) search identified studies on anti-CGRP monoclonal antibodies in patients with migraine over 65 up to October 2024. The review focuses on headache outcomes like reduction in monthly migraine days or monthly headache days, response rates (30%, 50%, 75%) and adverse effects of this specific population and/or against placebo, standard care, or younger patients. The quality of evidence was assessed using the GRADE tool. All eligible studies were included, along with additional articles presented narratively. Data from clinical trials and post-hoc analyses show comparable efficacy and safety between older and younger patients. Similarly, early real-life studies support the use of anti-CGRP monoclonal antibodies in patients over 65 years, showing similar response rates, reductions in monthly migraine days and adverse effects. Anti-CGRP monoclonal antibodies should likely be offered to patients over 65 although available evidence remains limited. Further studies analyzing specific data from this subgroup are necessary.


  • Open Access

    Grado de conocimiento de los pacientes con migraña sobre su tratamiento preventivo oral: resultados de un estudio nacional

    by A. López-Bravo, S. Quintas, A. Mínguez-Olaondo, A. Alpuente, C. Nieves-Castellanos, M. Pilar Navarro-Pérez, S. Pérez-Pereda, A. Layos Romero, C. Calle de Miguel, D. García-Azorín, et al.